Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines... Show more
a biotechnology, research and development company
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| VGIAX | 121.50 | 0.35 | +0.29% |
| Vanguard Growth & Income Adm | |||
| APHMX | 43.80 | 0.07 | +0.16% |
| Artisan Mid Cap Institutional | |||
| BRUMX | 19.29 | -0.07 | -0.36% |
| MFS Blended Research Value Equity R4 | |||
| WRGCX | 21.55 | -0.08 | -0.37% |
| Nomura Small Cap Growth C | |||
| SPSAX | 23.20 | -0.17 | -0.73% |
| Sterling Capital Behav Sm Cp Val Eq A | |||
A.I.dvisor indicates that over the last year, BNTC has been loosely correlated with VIR. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BNTC jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To BNTC | 1D Price Change % | ||
|---|---|---|---|---|
| BNTC | 100% | -2.99% | ||
| VIR - BNTC | 46% Loosely correlated | -2.93% | ||
| EDIT - BNTC | 43% Loosely correlated | -0.74% | ||
| BEAM - BNTC | 41% Loosely correlated | +1.13% | ||
| PRTA - BNTC | 40% Loosely correlated | +1.42% | ||
| GNLX - BNTC | 40% Loosely correlated | N/A | ||
More | ||||
BNTC saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on August 26, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 50 instances where the indicator turned negative. In 47 of the 50 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on September 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BNTC as a result. In 89 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
BNTC moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BNTC crossed bearishly below the 50-day moving average on September 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNTC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BNTC's RSI Indicator exited the oversold zone, 19 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for BNTC moved above the 200-day moving average on August 13, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +2.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNTC advanced for three days, in 231 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
BNTC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 127 of 147 cases where BNTC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. BNTC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.172) is normal, around the industry mean (25.951). P/E Ratio (2.890) is within average values for comparable stocks, (40.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.265). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. BNTC's P/S Ratio (2500.000) is slightly higher than the industry average of (436.793).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNTC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.